Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 26, 2026.

RNA metabolism in neurodegenerative disease

Elaine Y. Liu, Christopher P. Cali, Edward B. Lee

Disease Models & Mechanisms · 2017 · Review · CC BY

doi:10.1242/dmm.028613

Abstract

Aging-related neurodegenerative diseases are progressive and fatal neurological diseases that are characterized by irreversible neuron loss and gliosis. With a growing population of aging individuals, there is a pressing need to better understand the basic biology underlying these diseases. Although diverse disease mechanisms have been implicated in neurodegeneration, a common theme of altered RNA processing has emerged as a unifying contributing factor to neurodegenerative disease. RNA processing includes a series of distinct processes, including RNA splicing, transport and stability, as well as the biogenesis of non-coding RNAs. Here, we highlight how some of these mechanisms are altered in neurodegenerative disease, including the mislocalization of RNA-binding proteins and their sequestration induced by microsatellite repeats, microRNA biogenesis alterations and defective tRNA biogenesis, as well as changes to long-intergenic non-coding RNAs. We also highlight potential therapeutic interventions for each of these mechanisms.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 26, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Aging-related neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), frontotemporal degeneration (FTD) and amyotrophic lateral sclerosis (ALS), among others, are relentlessly progressive and uniformly fatal neurological diseases that are characterized by irreversible neuron loss and gliosis. Although dementia prevalence as a percentage of the elderly has declined in developed countries, the absolute number of dementia cases is growing as a result of an increase in the aging population. Thus, it is important for us to better understand the basic biological mechanisms that contribute to neurodegeneration.

Although much emphasis has been placed on the role of protein aggregates in neurodegenerative diseases, multiple lines of evidence also converge on altered RNA processing as a contributing factor in the pathogenesis of these diseases. Defects at all levels of gene regulation, from RNA synthesis, processing, function and degradation, are associated with disease-specific alterations in RNA-binding proteins (RBPs), and in non-coding RNAs, such as microRNAs (miRNA), transfer RNAs (tRNA) and long-noncoding RNAs (lncRNA). Given that these basic processes are essential for normal and properly regulated gene expression, it is increasingly clear that aberrations in these processes can contribute to disease. In this Review and accompanying poster, we highlight several key themes that explain how different classes of RNAs or RBPs can impair gene regulation. We also highlight specific examples with evidence to show that improper RNA metabolism is a critical feature of neurodegeneration.

RNA-binding proteins regulate RNA metabolism

RBPs are essentially required at all levels of RNA processing in both the nucleus and cytoplasm where transcription, splicing, RNA stabilization, and RNA degradation occur (see poster panel A). Two notable examples of RBP defects occur in familial and sporadic cases of ALS and FTD. ALS is a neurodegenerative disease that leads to the loss of upper and lower motor neurons from the motor cortex and spinal cord, respectively, whereas FTD is associated with neuronal loss in the temporal and frontal cortex. Despite different areas of neuronal atrophy, a common link between ALS and FTD patients is a nuclear RBP called TAR DNA-binding protein-43 (TDP-43). Post-mortem brains from human ALS and FTD patients show a characteristic mislocalization of TDP-43 from the nucleus into phosphorylated, ubiquitylated cytoplasmic TDP-43 aggregates (see poster panel A). Indeed, rare disease-causing mutations in TARDBP, the gene encoding TDP-43, suggest that TDP-43 dysfunction is sufficient to cause ALS, although the mechanism by which these mutations cause disease is unclear. TDP-43 functions ubiquitously in RNA processing, including splicing, stability and transport. Shortly after the discovery of TARDBP mutations, mutations in FUS, which encodes the nuclear protein fused in sarcoma (FUS) (also known as translated in liposarcoma, TLS), were identified in a subset of individuals with ALS, and FUS was revealed to be mislocalized to the cytoplasm. Similar to TDP-43, FUS interacts with serine arginine (SR) proteins involved in RNA splicing (Yang et al. 1998) and regulates transcription by recruiting RBPs through non-coding RNAs. An additional example of abnormally localized nuclear RBPs is evident in individuals with multisystem proteinopathy (MSP), in whom mutations in the gene encoding heterogeneous nucleoriboprotein particle A1 (HNRNPA1) and A2B1 (HNRNPA2B1) contribute to disease. MSP is characterized by the progressive degeneration of muscle, brain, motor neurons and bone, which sometimes manifests as ALS or FTD. Mutations in the gene encoding valosin-containing protein (VCP), a triple ATPase protein involved in many cellular functions including endolysosomal degradation, autophagy, and the ubiquitin proteasome system, also causes MSP.

It is thought that the loss of RBPs through their nuclear mislocalization and/or the toxicity caused by their cytoplasmic aggregation can lead to disease, but their relative contributions to disease remain unclear. Mouse models where antisense oligonucleotides (ASOs) against Tardbp depleted TDP-43, show altered global RNA expression affecting 601 genes, and specifically neuronal genes with long introns. To better understand the targets of these RBPs, TDP-43 and FUS have been immunoprecipitated from mice brains and rat primary neuronal cultures, revealing that these proteins bind to non-coding RNA sites, namely introns and 3′ untranslated regions (UTRs) of thousands of genes. Some of these genes include ncRNAs, like metastasis-associated lung adenocarcinoma transcript 1 (Malat1) and nuclear paraspeckle assembly transcript 1 (Neat1). Thus, it is possible that the loss of RBPs influences the processing of these non-coding RNAs and contributes to global RNA dysregulation (see poster panel A). Given that the depletion of these RBPs alters the expression of thousands of genes, it is likely that some, or even all of these changes contribute to disease pathogenesis.

The formation of cytoplasmic RNA granules that lead to cytoplasmic aggregates has also been proposed to be pathogenic. When cells are stressed, cytoplasmic RNA granules that contain stalled translational complexes are formed. TDP-43, FUS, and other RBPs, such as hnRNPA1 and A2B1, localize to stress granules. Indeed, RBPs with low complexity domains (LCD), such as TDP-43, FUS and hnRNPA1, can phase separate to create dynamic membrane-less organelles or liquid droplets that underlie the transient nature of stress granules. The liquid properties of these organelles are dependent on their constituents. Namely, the intrinsic properties, type, concentration of the RBP, RNAs that the RBPs are bound to and the concentration of the RNA greatly influence these RNA granules. For example, increasing the concentration of RBPs can reduce the liquid-like properties of these RNA granules, thereby promoting the formation of hydrogels and eventually an insoluble amyloid-like aggregate. Indeed, disease-associated mutations within the LCDs of RBPs can enhance prion-like properties, and accelerate the shift from liquid to solid and disrupt ribonucleoprotein (RNP) granule formation. At present, there is little evidence supporting amyloid-like fibrillar aggregates within neurons in ALS/FTD, but the relationship between other biophysical assemblies such as hydrogels, and neuronal aggregates is being investigated. Thus, the formation of liquid droplets is another mechanism by which RBP disruption could contribute to disease (see poster).

The formation of cytoplasmic aggregates has also been implicated in neurodegenerative disease. Several different rat and mouse models, in which wild-type or mutant TARDBP or mutant FUS bearing ALS-associated mutations are overexpressed, develop cytoplasmic aggregation and exhibit features of ALS and FTD, including cortical and hippocampal neuronal loss and motor deficits. However, none of these models has recapitulated the loss of endogenous nuclear TDP-43 or FUS. Despite the discrepancies between animal models and human pathology, there is in vitro evidence in support of the toxicity of cytoplasmic aggregates. Live tracking of rat primary cortical neurons to assess their survival shows that neurons with cytoplasmic TDP-43 have a greater risk of death, and that this risk depends on the amount of cytoplasmic TDP-43 present. This corroborates the finding that overexpression of FUS or TDP-43 in yeast results in cytoplasmic aggregation of these proteins. TDP-43 toxicity is dependent not only on its RNA-binding ability but also its C- terminus, the region where most disease-causing TARDBP mutations are found. Although there is no consensus on which mechanism is more toxic, it is likely that both nuclear clearance and cytoplasmic aggregation of RBPs contribute to disease. Indeed, an effort to parse the effects of nuclear TDP-43 loss and TDP-43 cytoplasmic aggregation in a mouse motor neuron-like hybrid cell line (NSC34) shows that both contribute relatively equally to cellular toxicity.

At present, potential therapeutic interventions are based on reducing the formation of toxic cytoplasmic aggregates. This is achieved in several ways, for example by: (1) activating the heat shock response; (2) using heat shock protein (Hsp)104 ‘disaggregases’; or (3) by modulating the ubiquitin proteasome system and autophagy. HSPs function as molecular chaperones and are involved in protein folding, protein trafficking and in coping with denatured proteins. Prior work has shown that the overexpression of an HSP, heat shock factor 1 (HSF1), in rat primary neuronal cultures overexpressing wild-type TDP-43 prevents cytoplasmic aggregation of TDP-43 by interacting with other HSPs to enhance refolding. This reduces toxicity in a human bone marrow neuroblast cell line (SH-SY5Y) overexpressing either wild-type or mutant TDP-43. Components of the heat shock response have also been engineered to remove aggregated proteins. Modified Hsp104 improves its disaggregation capabilities relative to the wild-type Hsp104, and is able to suppress FUS and TDP-43 toxicity in yeast. This provides a potential intervention to eliminate protein aggregates that contribute to toxicity. Enhancing components of the ubiquitin proteasome system or autophagy can also reduce these aggregates. For example, increasing cAMP levels with forskolin in human embryonic kidney cells (293A) enhances the ubiquitin proteasome system to clear aggregation-prone proteins, such as FUS and TDP-43, in cells overexpressing either wild-type or mutant forms of both proteins. Furthermore, two different studies show that using autophagy activators rescues motor dysfunction in transgenic FTD mice and also improves survival of neurons and astrocytes derived from human induced pluripotent stem cells from ALS patients with a TARDBP mutation. Until the toxic mechanism that underlies RBP pathology is uncovered, it is difficult to determine which therapeutic intervention will be the most beneficial to patients.

RBP sequestration by microsatellite repeat expansions

Microsatellite repeat expansion disorders are a class of neurodegenerative diseases caused by repetitive DNA elements that form long expansions within gene bodies or in untranslated regions. Over 25 human genes that contain repeat expansions have been identified to date. Some neurodegenerative diseases caused by microsatellite repeat expansion have been linked to the sequestration of RBPs by expanded repeat sequences; these expanded sequences sequester RBPs away from their target RNAs, thereby altering RNA splicing and metabolism (see poster panel B).

One example of altered RNA metabolism in neurological disease comes from the expansion of a CTG triplet in the 3′ UTR of the gene DMPK, which leads to myotonic dystrophy (DM). This expansion is transcribed into repeat RNA that forms aggregates, called RNA foci. These aggregates form within the nuclei of human-derived DM cells and recruit a class of RBPs that regulate alternative splicing, called the muscleblind-like proteins (MBNLs). By sequestering MBNLs into RNA foci, mutant DMPK renders MBNLs unable to regulate splicing and the polyadenylation of hundreds of target genes.

Similarly, repeat expansions associated with ALS/FTD and with Fragile X-associated tremor/ataxia syndrome (FXTAS) also sequester RBPs. In FXTAS, a short repeat expansion (<200 repeats) in the untranslated region of the gene FMR1 is transcribed into RNA and interacts with hnRNPs, MBNL1 and other RBPs (Iwajasjo et al., 2006;; ), thereby altering splicing and microRNA biogenesis in affected individuals.

In the most common inherited form of ALS/FTD, a hexanucleotide (G4C2) expansion in the first intron of the gene C9orf72 is bidirectionally transcribed into mutant RNA that forms aggregates in the nucleus. Current evidence shows that RBPs involved in splicing, such as hnRNPs and the SR splicing factors that comprise the spliceosome, are sequestered by mutant repeat-containing RNA (see poster panel B). Additionally, the repeat expansion, which normally regulates vesicle trafficking and autophagy. can interfere with transcription of the C9orf72 gene, resulting in haploinsufficiency of the protein product. Reduced transcription is due, in part, to hypermethylation of the mutant C9orf72 promoter. Hypermethylation is observed in about one third of C9orf72 mutation carriers and is associated with reduced mutant RNA accumulation and an attenuated clinical phenotype, suggesting that reduced transcription of mutant C9orf72 is actually protective against disease. Thus, altered RNA metabolism is clearly implicated in neurodegenerative diseases caused by repeat expansions.

Given that repeat expansions cause widespread disruption to RNA metabolism, it will be challenging to target downstream processes for therapeutic intervention. Therefore, the most promising therapeutic approaches are those that work upstream to reduce the amount of repeat-containing transcripts. Several studies have used ASOs to target C9orf72 and DM expansions for degradation via an RNAse H-mediated pathway. In fact, ASOs are already in clinical trial for the treatment of Huntington's disease (HD) and have been approved for the treatment of spinal muscular atrophy (SMA) (FDA, 2016, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm534611.htm). An alternative to targeting the repeat-containing transcript for degradation is to target proteins that are responsible for transcribing the repeat expansion. For instance, knockdown of the transcription elongation factor SUPT4H1 selectively decreases the repeat-containing RNA in C9orf72 expansion fibroblasts derived from human carriers. This strategy is attractive because transcription of the repeat is blocked in both the sense and antisense directions. A final therapeutic approach involves small molecules that target the expanded RNA to prevent their interactions with RBPs. Several of these compounds have been identified but are still in the early stages of development. Although the repeat-expansion disorders offer a clear therapeutic target, reversing alterations in RNA metabolism will be challenging in neurodegenerative diseases that lack a clear genetic etiology.

MicroRNA dysregulation in neurodegeneration

Genes can also be regulated post-transcriptionally via miRNAs, a class of small non-coding RNAs (18-25 nucleotides). miRNAs are initially transcribed by RNA polymerase II and then undergo sequential cleavage, first by Drosha and DGCR8 in the nucleus – to generate pre-miRNAs from pri-miRNAs – and then by Dicer after being exported into the cytoplasm, to generate a miRNA duplex. The miRNA duplex is unwound and one of the strands is incorporated into the RNA-induced silencing complex (RISC), where it binds to Argonaute (Agos) proteins. Agos then cleave the mRNA complementary to the miRNA or inhibit cap-dependent mRNA translation, both of which lead to translational repression.

There are two ways in which miRNA dysregulation contributes to neurodegeneration: alterations to miRNA biogenesis or to miRNA expression, both of which can affect disease-associated genes. A notable example of altered miRNA processing is evident in ALS/FTD through TDP-43 function. In normal neurons, TDP-43 binds to Drosha in the nucleus to cleave select pri-miRNAs and to Dicer in the cytoplasm to cleave some pre-miRNAs. In mouse neuroblastoma cells (Neuro2a), TDP-43 regulates neuronal outgrowth by modulating pri-miRNA-132 production. Using lysates from NSC-34 motor neuron cells overexpressing ALS-causing mutations in TARDBP and FUS in a cell-free dicing activity assay, Dicer function was shown to be altered resulting in an inhibition of miRNA biogenesis (see poster panel C). Conversely, activation of Dicer with enoxacin in an ALS mouse model that carries a mutation in the gene Cu/Zn superoxide dismustase 1 (SOD1) reverses miRNA downregulation and neuromuscular defects. This finding indicates that impairment of Dicer activity and miRNA downregulation likely contributes to ALS pathogenesis. Similarly, extensive miRNA dysregulation is seen in FXTAS patients, where FXTAS-associated CGG repeats sequester DGCR8 and prevent proper miRNA processing. In primary mouse cortical neuron cultures that express a plasmid containing toxic 60 CGG repeats, overexpression of DGCR8 is sufficient to reverse cellular toxicity. These examples demonstrate that improper miRNA processing leads to global miRNA dysregulation and contributes to different neurodegenerative diseases.

In addition to altered miRNA processing, specific miRNAs that affect certain disease-linked genes are also associated with neurodegenerative diseases (see poster). There are notable examples in Alzheimer's disease (AD) and ALS. AD is the most common form of dementia and is characterized by progressive memory loss, impaired cognitive function, and the inability to perform daily tasks. Pathologically, AD is defined by the presence of extracellular amyloid-β (Aβ) plaques and of intracellular hyper-phosphorylated neurofibrillary tangles composed of tau. Beta-site APP-cleaving enzyme 1 (BACE1) and γ-secretase cleave amyloid precursor protein (APP), resulting in Aβ peptides that accumulate into plaques. Multiple miRNAs have been implicated in Aβ production via BACE1 modulation and in tau phosphorylation that leads to hyperphosphorylated neurofibrillary tangle formation. Additionally, multiple miRNAs have also been implicated in ALS pathogenesis or as biomarkers of disease. For example, miR-23a is overexpressed in skeletal muscle biopsies from ALS patients. This miR-23a has been shown to regulate peroxisome proliferator-activated receptor γ coactivator-1α, a regulator of mitochondrial biogenesis and function, which is important for skeletal muscle function. Using spinal cord from individuals with ALS, miR-155-5p and miR-142-5p are upregulated whereas let-7e, miR-148-5p, miR-133b, miR-140-3p and miR-577 are downregulated. These miRNAs regulate neuronal homeostasis, pathogenesis of ALS and other neurodegeneration-related transcripts ranging from ubiquilin, RNA-binding protein fox-1 and reelin among others (see Table 1). Indeed, miRNA dysregulation can affect a range of disease-associated targets, which can contribute to neurodegeneration.

Altered miRNA signatures can also indicate potential diagnostic biomarkers. Indeed, various miRNA studies have identified differentially expressed miRNAs in post-mortem tissue or blood and in cerebrospinal fluid (CSF) that differ by disease stage (see Table 1). Furthermore, miRNA-based therapeutics, such as miRNA mimics or miRNA antagonists (antagomirs), have been designed to either reverse the downregulation or upregulation of disease-associated miRNAs, respectively. These have been investigated for the treatment of cancer and cardiovascular disease but few have been used to treat neurodegeneration. One example of an antagomir in neurodegeneration comes from an AD mouse model (Tg2576) characterized by elevated levels of Aβ and the presence of amyloid plaques. The treatment of Tg2576 with an antagomir against miR-206, which targets brain-derived neurotrophic factor (Bdnf), increases BDNF levels and improves memory function. Another example is based on the finding that miR-155 is increased in spinal cord from ALS patients and in an ALS mouse model with a mutation in SOD1. A locked nucleic acid (modified RNA nucleotide) anti-miR-155 reduces miR-155 levels in this mouse, thereby increasing survival and restoring the abnormal microglia and monocyte inflammatory signature. Because of the burgeoning importance of miRNAs in disease, it seems important to first investigate and develop an miRNA signature that is validated as a biomarker of disease by independent studies. Then, therapeutic interventions can be designed to target these specific miRNAs.

Other non-coding RNAs in neurodegeneration

With the discovery that other classes of non-coding (nc)RNAs are important for gene expression, it is perhaps unsurprising that alterations to some of these other ncRNAs, such as to tRNAs and lncRNAs, can also lead to neurodegeneration. tRNAs are essential for translation; they use aminoacyl-tRNA synthetase to attach amino acids to the tRNA molecule, which then transfer the appropriate amino acid to a growing polypeptide chain during protein synthesis. tRNA biogenesis entails the transcription and splicing of tRNAs by complexes that involve the proteins CLP1 (cleavage and polyadenylation factor I subunit 1) and TSEN (the tRNA-splicing endonuclease complex) (see poster panel D). Additionally, during cellular stress, angiogenin (ANG) cleaves tRNAs into fragments that might inhibit translation or target specific mRNAs for degradation as a cellular protective mechanism. Indeed, mutations in tRNA biogenesis components lead to neurodegeneration. Mutations in aminoacyl-tRNA synthetases are found in individuals with Charcot–Marie–Tooth, a disease of peripheral neuropathy. It is unclear why abnormalities in tRNA biogenesis result in different peripheral neuropathies but various mechanisms have been proposed, including: (1) loss of function of tRNA loading and subsequent protein translation inhibition; (2) a dominant-negative effect whereby mutant protein interferes with the wild-type protein activity; and (3) impaired axonal transport due to tRNA synthetase mutations, among others. A mutation in CLP1 (R140H) is a cause of progressive brain atrophy and microcephaly in humans. CLP1 R140H renders CLP1 unable to interact with TSEN, resulting in altered tRNA processing (see poster panel D). Mutations in ANG that might contribute to the loss of ANG function also occur in ALS. Altered translation can also contribute to neurodegenerative disease. Specifically, a mutation in GTPBP2, which encodes a ribosome rescue factor, leads to global ribosomal stalling by epistatically interacting with an isodecoder of nuclear-encoded tRNAs, called n-Tra20. This aberrant interaction ultimately leads to neurodegeneration via altered translation. These studies only provide a snapshot of how aberrations in tRNA processing can lead to neurodegeneration.

lncRNAs have also been implicated in neurodegenerative diseases (see poster panel E). These RNAs are longer than 200 nucleotides and fulfill various functions, including acting as scaffolds for chromatin modifiers and nuclear paraspeckles, as transcriptional co-regulators, and even as decoys for other RNAs. Alterations in lncRNAs can affect any one of these processes, thereby contributing to neurodegeneration. lncRNAs associated with disease can post-transcriptionally increase gene expression, as seen with the lncRNAs, BACE1-antisense (AS) and lnc-SCA7 (official symbol ATXN7L3B). BACE1-AS is increased in AD brains and competes with miRNA-545-5p binding to stabilize BACE1 mRNA. This is associated with increased BACE1 expression and with the formation of the Aβ peptides that contribute to AD pathology (see poster panel E). In spinocerebellar ataxia type 7 (SCA7), mutant CAG repeats in the ATXN7 gene contribute to cerebellar neuronal death. Normally, ATXN7L3B regulates ATXN7, which is loaded into a transcriptional activator complex, called STAGA. STAGA promotes miR-124 biogenesis, which in turn, represses ATXN7L3B expression. In SCA7, mutant CAG repeats promote mutant ATXN7 protein levels, which reduce STAGA activity. This consequently reduces miR-124 biogenesis, increases ATXN7L3B expression and promotes more mutant ATXN7 production. Other examples of genes with altered lncRNAs include MALAT1 and NEAT1, which are important for splicing and synapse formation. Both of these RNAs are bound by TDP-43 and FUS. MALAT1 and NEAT1 have been shown to colocalize in nuclear paraspeckles, sites where RNA is retained to control gene expression during different cell processes (see poster panel E). Additionally, NEAT1 is upregulated in the HD brain, which is thought to make cells susceptible to oxidative stress. Other HD-associated genes with lncRNAs include TUG1, which is increased in HD and which normally associates with polycomb repressive complex 2 (PRC2) to repress gene expression (see poster). Thus, lncRNAs are likely to influence gene expression post-transcriptionally to contribute to neurodegenerative disease.

Therapies designed to target lncRNAs involve inhibiting the function of lncRNAs usually by: (1) blocking the interaction of the antisense and sense mRNA by degrading the antisense strand, which leads to the transcriptional repression of the gene; (2) using aptamers to bind and inhibit lncRNA structures and prevent their activity; and (3) employing small molecules that inhibit lncRNA interactions. Although it has been shown that treating a mutant APP-expressing human HEK-SW cell line with siRNA against BACE1-AS leads to reduced Aβ, this finding has not been validated in an AD mouse model or human patients. A better understanding of how specific lncRNAs contribute to the disease phenotype is integral to designing better-targeted therapeutics for these diseases.

Conclusions

Neurodegenerative diseases occur by different means and present with various pathologies. However, it is becoming increasingly clear that altered or defective RNA metabolism, including mislocalized RBPs and aberrant ncRNA biogenesis or expression, can contribute to neurodegeneration. Because numerous disease-associated pathways are perturbed in these neurodegenerative diseases (as summarized in the accompanying poster), it is unlikely that targeting only one of these modalities will lead to a complete cure. Nonetheless, reversing some of these RNA aberrations could prove to be effective in modifying the incessantly downward disease trajectory associated with these diseases. Perhaps by modifying disease progression, such approaches could provide a significant benefit for those afflicted by neurodegenerative disease.

References 177

  1. 1.

    Alami N. H., Smith R. B., Carrasco M. A., Williams L. A., Winborn C. S., Han S. S. W., Kiskinis E., Winborn B., Freibaum B. D., Kanagaraj A. et al. (2014 ). Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron 81, 536-543.

    Not in our library10.1016/j.neuron.2013.12.018

  2. 2.

    Anderson P. and Ivanov P. (2014 ). tRNA fragments in human health and disease. FEBS Lett. 588, 4297-4304.

    Not in our library10.1016/j.febslet.2014.09.001

  3. 3.

    Antonellis A., Ellsworth R. E., Sambuughin N., Puls I., Abel A., Lee-Lin S.-Q., Jordanova A., Kremensky I., Christodoulou K., Middleton L. T. et al. (2003 ). Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V. Am. J. Hum. Genet. 72, 1293-1299.

    Not in our library10.1086/375039

  4. 4.

    Aoki Y., Manzano R., Lee Y., Dafinca R., Aoki M., Douglas A. G. L., and Wood M. J. A. (2017 ). C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia. Brain 140, 887-897.

    Not in our library10.1093/brain/awx024

  5. 5.

    Ash P. E. A., Bieniek K. F., Gendron T. F., Caulfield T., Lin W.-L., DeJesus-Hernandez M., van Blitterswijk M. M., Jansen-West K., Paul J. W., Rademakers R. et al. (2013 ). Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77, 639-646.

    Not in our library10.1016/j.neuron.2013.02.004

  6. 6.

    Barmada S. J., Skibinski G., Korb E., Rao E. J., Wu J. Y. and Finkbeiner S. (2010 ). Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J. Neurosci. 30, 639-649.

    Not in our library10.1523/jneurosci.4988-09.2010

  7. 7.

    Barmada S. J., Serio A., Arjun A., Bilican B., Daub A., Ando D. M., Tsvetkov A., Pleiss M., Li X., Peisach D. et al. (2014 ). Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nat. Chem. Biol. 10, 677-685.

    Not in our library10.1038/nchembio.1563

  8. 8.

    Batra R., Charizanis K., Manchanda M., Mohan A., Li M., Finn D. J., Goodwin M., Zhang C., Sobczak K., Thornton C. A. et al. (2014 ). Loss of MBNL leads to disruption of developmentally regulated alternative polyadenylation in RNA-mediated disease. Mol. Cell 56, 311-322.

    Not in our library10.1016/j.molcel.2014.08.027

  9. 9.

    Belzil V. V., Gendron T. F. and Petrucelli L. (2013 ). RNA-mediated toxicity in neurodegenerative disease. Mol. Cell. Neurosci. 56, 406-419.

    Not in our library10.1016/j.mcn.2012.12.006

  10. 10.

    Bentmann E., Haass C. and Dormann D. (2013 ). Stress granules in neurodegeneration--lessons learnt from TAR DNA binding protein of 43 kDa and fused in sarcoma. FEBS J. 280, 4348-4370.

    Not in our library10.1111/febs.12287

  11. 11.

    Bernard D., Prasanth K. V., Tripathi V., Colasse S., Nakamura T., Xuan Z., Zhang M. Q., Sedel F., Jourdren L., Coulpier F. et al. (2010 ). A long nuclear-retained non-coding RNA regulates synaptogenesis by modulating gene expression. EMBO J. 29, 3082-3093.

    Not in our library10.1038/emboj.2010.199

  12. 12.

    Broderick J. A. and Zamore P. D. (2011 ). MicroRNA therapeutics. Gene Ther. 18, 1104-1110.

    Not in our library10.1038/gt.2011.50

  13. 13.

    Brook J. D., McCurrach M. E., Harley H. G., Buckler A. J., Church D., Aburatani H., Hunter K., Stanton V. P., Thirion J.-P. and Hudson T. (1992 ). Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3’ end of a transcript encoding a protein kinase family member. Cell 68, 799-808.

    Not in our library10.1016/0092-8674(92)90154-5

  14. 14.

    Buratti E., Dörk T., Zuccato E., Pagani F., Romano M. and Baralle F. E. (2001 ). Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J. 20, 1774-1784.

    Not in our library10.1093/emboj/20.7.1774

  15. 15.

    Burberry A., Suzuki N., Wang J.-Y., Moccia R., Mordes D. A., Stewart M. H., Suzuki-Uematsu S., Ghosh S., Singh A., Merkle F. T. et al. (2016 ). Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci. Transl. Med. 8, 347ra93

    Not in our library10.1126/scitranslmed.aaf6038

  16. 16.

    Butovsky O., Jedrychowski M. P., Cialic R., Krasemann S., Murugaiyan G., Fanek Z., Greco D. J., Wu P. M., Doykan C. E., Kiner O. et al. (2015 ). Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. Ann. Neurol. 77, 75-99.

    Not in our library10.1002/ana.24304

  17. 17.

    Campuzano V., Montermini L., Molto M. D., Pianese L., Cossee M., Cavalcanti F., Monros E., Rodius F., Duclos F., Monticelli A. et al. (1996 ). Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271, 1423-1427.

    Not in our library10.1126/science.271.5254.1423

  18. 18.

    Cascella R., Capitini C., Fani G., Dobson C. M., Cecchi C. and Chiti F. (2016 ). Quantification of the relative contributions of loss-of-function and gain-of-function mechanisms in TAR DNA-binding protein 43 (TDP-43) proteinopathies. J. Biol. Chem. 291, 19437-19448.

    Not in our library10.1074/jbc.m116.737726

  19. 19.

    Cech T. R. and Steitz J. A. (2014 ). The noncoding RNA revolution-trashing old rules to forge new ones. Cell 157, 77-94.

    Not in our library10.1016/j.cell.2014.03.008

  20. 20.
    The heat shock response plays an important role in TDP-43 clearance: evidence for dysfunction in amyotrophic lateral sclerosis · 2016
    No notice
  21. 21.

    Chen-Plotkin A. S., Unger T. L., Gallagher M. D., Bill E., Kwong L. K., Volpicelli-Daley L., Busch J. I., Akle S., Grossman M., Van Deerlin V. et al. (2012 ). TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. J. Neurosci. 32, 11213-11227.

    Not in our library10.1523/jneurosci.0521-12.2012

  22. 22.

    Chendrimada T. P., Gregory R. I., Kumaraswamy E., Norman J., Cooch N., Nishikura K. and Shiekhattar R. (2005 ). TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 436, 740-744.

    Not in our library10.1038/nature03868

  23. 23.

    Ciura S., Lattante S., Le Ber I., Latouche M., Tostivint H., Brice A. and Kabashi E. (2013 ). Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Ann. Neurol. 74, 180-187.

    Not in our library10.1002/ana.23946

  24. 24.

    Cogswell J. P., Ward J., Taylor I. A., Waters M., Shi Y., Cannon B., Kelnar K., Kemppainen J., Brown D., Chen C. et al. (2008 ). Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J. Alzheimers Dis. 14, 27-41.

    Not in our library10.3233/jad-2008-14103

  25. 25.
    Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions · 2014
    No notice
  26. 26.

    Costessi L., Porro F., Iaconcig A. and Muro A. F. (2014 ). TDP-43 regulates β-adducin (Add2) transcript stability. RNA Biol. 11, 1280-1290.

    Not in our library10.1080/15476286.2014.996081

  27. 27.

    Courchaine E. M., Lu A. and Neugebauer K. M. (2016 ). Droplet organelles? EMBO J. 35, 1603-1612.

    Not in our library10.15252/embj.201593517

  28. 28.

    Cui J. G., Li Y. Y., Zhao Y., Bhattacharjee S. and Lukiw W. J. (2010 ). Differential regulation of interleukin-1 receptor-associated kinase-1 (IRAK-1) and IRAK-2 by microRNA-146a and NF-kappaB in stressed human astroglial cells and in Alzheimer disease. J. Biol. Chem. 285, 38951-38960.

    Not in our library10.1074/jbc.m110.178848

  29. 29.
    RNA Gain-of-Function in Spinocerebellar Ataxia Type 8 · 2009
    No notice
  30. 30.

    Davis B. M., McCurrach M. E., Taneja K. L., Singer R. H. and Housman D. E. (1997 ). Expansion of a CUG trinucleotide repeat in the 3′ untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts. Proc. Natl. Acad. Sci. USA 94, 7388-7393.

    Not in our library10.1073/pnas.94.14.7388

  31. 31.

    De Felice B., Annunziata A., Fiorentino G., Borra M., Biffali E., Coppola C., Cotrufo R., Brettschneider J., Giordana M. L., Dalmay T. et al. (2014 ). miR-338-3p is over-expressed in blood, CFS, serum and spinal cord from sporadic amyotrophic lateral sclerosis patients. Neurogenetics 15, 243-253.

    Not in our library10.1007/s10048-014-0420-2

  32. 32.

    DeJesus-Hernandez M., Mackenzie I. R., Boeve B. F., Boxer A. L., Baker M., Rutherford N. J., Nicholson A. M., Finch N. A., Flynn H., Adamson J. et al. (2011 ). Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245-256.

    Not in our library10.1016/j.neuron.2011.09.011

  33. 33.

    Disney M. D., Liu B., Yang W.-Y., Sellier C., Tran T., Charlet-Berguerand N. and Childs-Disney J. L. (2012 ). A small molecule that targets r(CGG)(exp) and improves defects in fragile X-associated tremor ataxia syndrome. ACS Chem. Biol. 7, 1711-1718.

    Not in our library10.1021/cb300135h

  34. 34.

    Donnelly C. J., Zhang P., Pham J. T., Heusler A. R., Mistry N. A., Vidensky S., Daley E. L., Poth E. M., Fines D. M., Maragakis N. et al. (2013 ). RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 80, 415-428.

    Not in our library10.1016/j.neuron.2013.10.015

  35. 35.

    Durr A. (2010 ). Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol. 9, 885-894.

    Not in our library10.1016/s1474-4422(10)70183-6

  36. 36.

    Elden A. C., Kim H.-J. J., Hart M. P., Chen-Plotkin A. S., Johnson B. S., Fang X., Armakola M., Geser F., Greene R., Lu M. M. et al. (2010 ). Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466, 1069-1075.

    Not in our library10.1038/nature09320

  37. 37.

    Emde A., Eitan C., Liou L.-L., Libby R. T., Rivkin N., Magen I., Reichenstein I., Oppenheim H., Eilam R., Silvestroni A. et al. (2015 ). Dysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: a new mechanism for ALS. EMBO J. 34, 2633-2651.

    Not in our library10.15252/embj.201490493

  38. 38.

    Faghihi M. A., Modarresi F., Khalil A. M., Wood D. E., Sahagan B. G., Morgan T. E., Finch C. E., St. Laurent G., Kenny P. and Wahlestedt C. (2008 ). Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat. Med. 14, 723-730.

    Not in our library10.1038/nm1784

  39. 39.

    Fatemi R. P., Velmeshev D. and Faghihi M. A. (2014 ). De-repressing LncRNA-targeted genes to upregulate gene expression: focus on small molecule therapeutics. Mol. Ther. Nucleic Acids 3, e196

    Not in our library10.1038/mtna.2014.45

  40. 40.

    Figueroa-Romero C., Hur J., Lunn J. S., Paez-Colasante X., Bender D. E., Yung R., Sakowski S. A. and Feldman E. L. (2016 ). Expression of microRNAs in human post-mortem amyotrophic lateral sclerosis spinal cords provides insight into disease mechanisms. Mol. Cell. Neurosci. 71, 34-45.

    Not in our library10.1016/j.mcn.2015.12.008

  41. 41.

    Fox A. H. and Lamond A. I. (2010 ). Paraspeckles. Cold Spring Harbor Perspect. Biol. 2, a000687

    Not in our library10.1101/cshperspect.a000687

  42. 42.

    Fu H., Feng J., Liu Q., Sun F., Tie F., Zhu J., Xing R., Sun Z. and Zheng X. (2009 ). Stress induces tRNA cleavage by angiogenin in mammalian cells. FEBS Lett. 583, 437-442.

    Not in our library10.1016/j.febslet.2008.12.043

  43. 43.

    Gaughwin P. M., Ciesla M., Lahiri N., Tabrizi S. J., Brundin P. and Björkqvist M. (2011 ). Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease. Hum. Mol. Genet. 20, 2225-2237.

    Not in our library10.1093/hmg/ddr111

  44. 44.
    Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 · 2016
    Corrected
  45. 45.
    Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS · 2013
    No notice
  46. 46.

    Gitcho M. A., Baloh R. H., Chakraverty S., Mayo K., Norton J. B., Levitch D., Hatanpaa K. J., White C. L., Bigio E. H., Caselli R. et al. (2008 ). TDP-43 A315T mutation in familial motor neuron disease. Ann. Neurol. 63, 535-538.

    Not in our library10.1002/ana.21344

  47. 47.

    Goodwin M., Mohan A., Batra R., Lee K.-Y., Charizanis K., Gómez F. J. F., Eddarkaoui S., Sergeant N., Buée L., Kimura T. et al. (2015 ). MBNL sequestration by toxic RNAs and RNA misprocessing in the myotonic dystrophy brain. Cell Rep. 12, 1159-1168.

    Not in our library10.1016/j.celrep.2015.07.029

  48. 48.

    Grabczyk E. and Usdin K. (2000 ). The GAATTC triplet repeat expanded in Friedreich's ataxia impedes transcription elongation by T7 RNA polymerase in a length and supercoil dependent manner. Nucleic Acids Res. 28, 2815-2822.

    Not in our library10.1093/nar/28.14.2815

  49. 49.

    Greenway M. J., Alexander M. D., Ennis S., Traynor B. J., Corr B., Frost E., Green A. and Hardiman O. (2004 ). A novel candidate region for ALS on chromosome 14q11. 2. Neurology 63, 1936-1938.

    Not in our library10.1212/01.wnl.0000144344.39103.f6

  50. 50.

    Greenway M. J., Andersen P. M., Russ C., Ennis S., Cashman S., Donaghy C., Patterson V., Swingler R., Kieran D., Prehn J. et al. (2006 ). ANG mutations segregate with familial and'sporadic'amyotrophic lateral sclerosis. Nat. Genet. 38, 411-413.

    Not in our library10.1038/ng1742

  51. 51.

    Guo L. and Shorter J. (2015 ). It's raining liquids: RNA tunes viscoelasticity and dynamics of membraneless organelles. Mol. Cell 60, 189-192.

    Not in our library10.1016/j.molcel.2015.10.006

  52. 52.

    Halliday G., Bigio E. H., Cairns N. J., Neumann M., Mackenzie I. R. A. and Mann D. M. A. (2012 ). Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects. Acta Neuropathol. 124, 373-382.

    Not in our library10.1007/s00401-012-1030-4

  53. 53.

    Hardy J. and Selkoe D. (2002 ). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.

    Not in our library10.1126/science.1072994

  54. 54.

    Hébert S. S., Horré K., Nicolaï L., Papadopoulou A. S., Mandemakers W., Silahtaroglu A. N., Kauppinen S., Delacourte A. and Strooper B. (2008 ). Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc. Natl. Acad. Sci. USA 105, 6415-6420.

    Not in our library10.1073/pnas.0710263105

  55. 55.
    miR-10b-5p expression in Huntington’s disease brain relates to age of onset and the extent of striatal involvement · 2015
    No notice
  56. 56.
    FUS Transgenic Rats Develop the Phenotypes of Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degeneration · 2011
    No notice
  57. 57.

    Huber K. M., Gallagher S. M., Warren S. T. and Bear M. F. (2002 ). Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc. Natl. Acad. Sci. USA 99, 7746-7750.

    Not in our library10.1073/pnas.122205699

  58. 58.

    Igaz L. M., Kwong L. K., Lee E. B., Chen-Plotkin A., Swanson E., Unger T., Malunda J., Xu Y., Winton M. J., Trojanowski J. Q. et al. (2011 ). Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J. Clin. Invest. 121, 726-738.

    Not in our library10.1172/jci44867

  59. 59.

    Ishimura R., Nagy G., Dotu I., Zhou H., Yang X.-L., Schimmel P., Senju S., Nishimura Y., Chuang J. and Ackerman S. (2014 ). Ribosome stalling induced by mutation of a CNS-specific tRNA causes neurodegeneration. Science 345, 455-459.

    Not in our library10.1126/science.1249749

  60. 60.

    Ivanov P., Emara M. M., Villen, J., Gygi S. P. and Anderson P. (2011 ). Angiogenin-induced tRNA fragments inhibit translation initiation. Mol. Cell 43, 613-623.

    Not in our library10.1016/j.molcel.2011.06.022

  61. 61.

    Iwahashi C. K., Yasui D. H., An H.-J., Greco C. M., Tassone F., Nannen K., Babineau B., Lebrilla C. B., Hagerman R. J. and Hagerman P. J. (2006 ). Protein composition of the intranuclear inclusions of FXTAS. Brain 129, 256-271.

    Not in our library10.1093/brain/awh650

  62. 62.
    MicroRNA-146a: A Key Regulator of Astrocyte-Mediated Inflammatory Response · 2012
    No notice
  63. 63.

    Jackrel M., DeSantis M., Martinez B., Castellano L., Stewart R., Caldwell K., Caldwell G. and Shorter J. (2014 ). Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events. Cell 156, 170-182.

    Not in our library10.1016/j.cell.2013.11.047

  64. 64.

    Jiang J. and Cleveland D. W. (2016 ). Bidirectional transcriptional inhibition as therapy for ALS/FTD caused by repeat expansion in C9orf72. Neuron 92, 1160-1163.

    Not in our library10.1016/j.neuron.2016.12.008

  65. 65.

    Jiang H., Mankodi A., Swanson M. S., Moxley R. T. and Thornton C. A. (2004 ). Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum. Mol. Genet. 13, 3079-3088.

    Not in our library10.1093/hmg/ddh327

  66. 66.

    Jiang J., Zhu Q., Gendron T., Saberi S., McAlonis-Downes M., Seelman A., Stauffer J., Jafar-Nejad P., Drenner K., Schulte D. et al. (2016 ). Gain of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs. Neuron 90, 535-550.

    Not in our library10.1016/j.neuron.2016.04.006

  67. 67.

    Jin P., Duan R., Qurashi A., Qin Y., Tian D., Rosser T. C., Liu H., Feng Y. and Warren S. T. (2007 ). Pur alpha binds to rCGG repeats and modulates repeat-mediated neurodegeneration in a Drosophila model of fragile X tremor/ataxia syndrome. Neuron 55, 556-564.

    Not in our library10.1016/j.neuron.2007.07.020

  68. 68.

    Johnson R. (2012 ). Long non-coding RNAs in Huntington's disease neurodegeneration. Neurobiol. Dis. 46, 245-254.

    Not in our library10.1016/j.nbd.2011.12.006

  69. 69.

    Johnson R. and Buckley N. J. (2009 ). Gene dysregulation in Huntington's disease: REST, microRNAs and beyond. Neuromolecular Med. 11, 183-199.

    Not in our library10.1007/s12017-009-8063-4

  70. 70.

    Johnson B. S., McCaffery J. M., Lindquist S. and Gitler A. D. (2008 ). A yeast TDP-43 proteinopathy model: exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. 105, 6439-6444.

    Not in our library10.1073/pnas.0802082105

  71. 71.

    Johnson B. S., Snead D., Lee J. J., McCaffery J. M., Shorter J. and Gitler A. D. (2009 ). TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J. Biol. Chem. 284, 20329-20339.

    Not in our library10.1074/jbc.m109.010264

  72. 72.
    MicroRNA-22 (miR-22) Overexpression Is Neuroprotective via General Anti-Apoptotic Effects and May also Target Specific Huntington’s Disease-Related Mechanisms · 2013
    No notice
  73. 73.

    Kabashi E., Valdmanis P. N., Dion P., Spiegelman D., McConkey B. J., Vande V. C., Bouchard J.-P. P., Lacomblez L., Pochigaeva K., Salachas F. et al. (2008 ). TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 40, 572-574.

    Not in our library10.1038/ng.132

  74. 74.

    Karaca E., Weitzer S., Pehlivan D., Shiraishi H., Gogakos T., Hanada T., Jhangiani S. N., Wiszniewski W., Withers M., Campbell I. M. et al. (2014 ). Human CLP1 mutations alter tRNA biogenesis, affecting both peripheral and central nervous system function. Cell 157, 636-650.

    Not in our library10.1016/j.cell.2014.02.058

  75. 75.

    Kato M., Han T. W., Xie S., Shi K., Du X., Wu L. C., Mirzaei H., Goldsmith E. J., Longgood J., Pei J. et al. (2012 ). Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels. Cell 149, 753-767.

    Not in our library10.1016/j.cell.2012.04.017

  76. 76.

    Kawahara Y. and Mieda-Sato A. (2012 ). TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. Proc. Natl. Acad. Sci. USA 109, 3347-3352.

    Not in our library10.1073/pnas.1112427109

  77. 77.

    Khalil A. M., Guttman M., Huarte M., Garber M., Raj A., Morales D., Thomas K., Presser A., Bernstein B. E., Oudenaarden A. et al. (2009 ). Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc. Natl. Acad. Sci. USA 106, 11667-11672.

    Not in our library10.1073/pnas.0904715106

  78. 78.

    Kim J., Inoue K., Ishii J., Vanti W. B., Voronov S. V., Murchison E., Hannon G. and Abeliovich A. (2007 ). A MicroRNA feedback circuit in midbrain dopamine neurons. Science 317, 1220-1224.

    Not in our library10.1126/science.1140481

  79. 79.

    Kim H. J., Kim N. C., Wang Y.-D., Scarborough E. A., Moore J., Diaz Z., MacLea K. S., Freibaum B., Li S., Molliex A. et al. (2013 ). Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 495, 467-473.

    Not in our library10.1038/nature11922

  80. 80.

    Kim W., Lee Y., McKenna N. D., Yi M., Simunovic F., Wang Y., Kong B., Rooney R. J., Seo H., Stephens R. M. et al. (2014 ). miR-126 contributes to Parkinson's disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling. Neurobiol. Aging 35, 1712-1721.

    Not in our library10.1016/j.neurobiolaging.2014.01.021

  81. 81.

    Kiriakidou M., Tan G. S., Lamprinaki S., De Planell-Saguer M., Nelson P. T. and Mourelatos Z. (2007 ). An mRNA m7G cap binding-like motif within human Ago2 represses translation. Cell 129, 1141-1151.

    Not in our library10.1016/j.cell.2007.05.016

  82. 82.

    Kordasiewicz H. B., Stanek L. M., Wancewicz E. V., Mazur C., McAlonis M. M., Pytel K. A., Artates J. W., Weiss A., Cheng S. H., Shihabuddin L. S. et al. (2012 ). Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 74, 1031-1044.

    Not in our library10.1016/j.neuron.2012.05.009

  83. 83.

    Kramer N. J., Carlomagno Y., Zhang Y.-J. J., Almeida S., Cook C. N., Gendron T. F., Prudencio M., Van Blitterswijk M., Belzil V., Couthouis J. et al. (2016 ). Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts. Science 353, 708-712.

    Not in our library10.1126/science.aaf7791

  84. 84.
    Promiscuous interactions and protein disaggregases determine the material state of stress-inducible RNP granules · 2015
    No notice
  85. 85.

    Kwiatkowski T. J., Bosco D. A., LeClerc A. L., Tamrazian E., Vanderburg C. R., Russ C., Davis A., Gilchrist J., Kasarskis E. J., Munsat T. et al. (2009 ). Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323, 1205-1208.

    Not in our library10.1126/science.1166066

  86. 86.

    Lagier-Tourenne C., Polymenidou M., Hutt K. R., Vu A. Q., Baughn M., Huelga S. C., Clutario K. M., Ling S.-C., Liang T. Y., Mazur C. et al. (2012 ). Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat. Neurosci. 15, 1488-1497.

    Not in our library10.1038/nn.3230

  87. 87.

    Lagier-Tourenne C., Baughn M., Rigo F., Sun S., Liu P., Li H.-R., Jiang J., Watt A. T., Chun S., Katz M. et al. (2013 ). Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl. Acad. Sci. USA 110, E4530-E4539.

    Not in our library10.1073/pnas.1318835110

  88. 88.

    Langa K. M., Larson E. B., Crimmins E. M., Faul J. D., Levine D. A., Kabeto M. U. and Weir D. R. (2017 ). A Comparison of the prevalence of dementia in the united states in 2000 and 2012. JAMA Intern. Med. 177, 51-58.

    Not in our library10.1001/jamainternmed.2016.6807

  89. 89.
    Alteration of the microRNA network during the progression of Alzheimer's disease · 2013
    No notice
  90. 90.

    Lee Y., Ahn C., Han J., Choi H., Kim J., Yim J., Lee J., Provost P., Rådmark O., Kim S. et al. (2003 ). The nuclear RNase III Drosha initiates microRNA processing. Nature 425, 415-419.

    Not in our library10.1038/nature01957

  91. 91.

    Lee S.-T. T., Chu K., Jung K.-H. H., Kim J. H., Huh J.-Y. Y., Yoon H., Park D.-K. K., Lim J.-Y. Y., Kim J.-M. M., Jeon D. et al. (2012 ). miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model. Ann. Neurol. 72, 269-277.

    Not in our library10.1002/ana.23588

  92. 92.
    Hexanucleotide Repeats in ALS/FTD Form Length-Dependent RNA Foci, Sequester RNA Binding Proteins, and Are Neurotoxic · 2013
    Not checked
  93. 93.

    Lehmann S. M., Krüger C., Park B., Derkow K., Rosenberger K., Baumgart J., Trimbuch T., Eom G., Hinz M., Kaul D. et al. (2012 ). An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration. Nat. Neurosci. 15, 827-835.

    Not in our library10.1038/nn.3113

  94. 94.

    Li Y. R., King O. D., Shorter J. and Gitler A. D. (2013 ). Stress granules as crucibles of ALS pathogenesis. J. Cell Biol. 201, 361-372.

    Not in our library10.1083/jcb.201302044

  95. 95.

    Lin Y., Protter D. S., Rosen M. K. and Parker R. (2015 ). Formation and maturation of phase-separated liquid droplets by RNA-binding proteins. Mol. Cell 60, 208-219.

    Not in our library10.1016/j.molcel.2015.08.018

  96. 96.

    Lindquist S. and Craig E. A. (1988 ). The heat-shock proteins. Annu. Rev. Genet. 22, 631-677.

    Not in our library10.1146/annurev.ge.22.120188.003215

  97. 97.

    Ling S.-C., Albuquerque C. P., Han J. S., Lagier-Tourenne C., Tokunaga S., Zhou H. and Cleveland D. W. (2010 ). ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proc. Natl. Acad. Sci. USA 107, 13318-13323.

    Not in our library10.1073/pnas.1008227107

  98. 98.

    Ling S.-C., Polymenidou M. and Cleveland D. W. (2013 ). Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 79, 416-438.

    Not in our library10.1016/j.neuron.2013.07.033

  99. 99.

    Ling J. P., Pletnikova O., Troncoso J. C. and Wong P. C. (2015 ). TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science 349, 650-655.

    Not in our library10.1126/science.aab0983

  100. 100.

    Liquori C. L., Ricker K., Moseley M. L., Jacobsen J. F., Kress W., Naylor S. L., Day J. W. and Ranum L. P. (2001 ). Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 293, 864-867.

    Not in our library10.1126/science.1062125

  101. 101.

    Liu X., Li D., Zhang W., Guo M. and Zhan Q. (2012 ). Long non-coding RNA gadd7 interacts with TDP-43 and regulates Cdk6 mRNA decay. EMBO J. 31, 4415-4427.

    Not in our library10.1038/emboj.2012.292

  102. 102.

    Liu E., Russ J., Wu K., Neal D., Suh E., McNally A., Irwin D. J., Van Deerlin V. M. and Lee E. B. (2014 ). C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD. Acta Neuropathol. 128, 525-541.

    Not in our library10.1007/s00401-014-1286-y

  103. 103.

    Lokireddy S., Kukushkin N. and Goldberg A. (2015 ). cAMP-induced phosphorylation of 26S proteasomes on Rpn6/PSMD11 enhances their activity and the degradation of misfolded proteins. Proc. Natl Acad. Sci. USA 112, E7176-E7185.

    Not in our library10.1073/pnas.1522332112

  104. 104.

    Loureiro J. R., Oliveira C. L. and Silveira I. (2016 ). Unstable repeat expansions in neurodegenerative diseases: nucleocytoplasmic transport emerges on the scene. Neurobiol. Aging 39, 174-183.

    Not in our library10.1016/j.neurobiolaging.2015.12.007

  105. 105.

    Lukiw W. J. and Alexandrov P. N. (2012 ). Regulation of complement factor H (CFH) by multiple miRNAs in Alzheimer's disease (AD) brain. Mol. Neurobiol. 46, 11-19.

    Not in our library10.1007/s12035-012-8234-4

  106. 106.

    Luu L. M., Nguyen L., Peng S., Lee J., Lee H. Y., Wong C.-H., Hergenrother P. J., Chan H. Y. E. and Zimmerman S. C. (2016 ). A potent inhibitor of protein sequestration by expanded triplet (CUG) repeats that shows phenotypic improvements in a drosophila model of myotonic dystrophy. ChemMedChem 11, 1428-1435.

    Not in our library10.1002/cmdc.201600081

  107. 107.

    MacDonald M. E., Barnes G., Srinidhi J., Duyao M. P., Ambrose C. M., Myers R. H., Gray J., Conneally P. M., Young A. and Penney J. (1993 ). Gametic but not somatic instability of CAG repeat length in Huntington's disease. J. Med. Genet. 30, 982-986.

    Not in our library10.1136/jmg.30.12.982

  108. 108.

    Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S. W. et al. (1996 ). Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506.

    Not in our library10.1016/s0092-8674(00)81369-0

  109. 109.

    McMillan C. T., Russ J., Wood E. M., Irwin D. J., Grossman M., McCluskey L., Elman L., Van Deerlin V. and Lee E. B. (2015 ). C9orf72 promoter hypermethylation is neuroprotective: neuroimaging and neuropathologic evidence. Neurology 84, 1622-1630.

    Not in our library10.1212/wnl.0000000000001495

  110. 110.

    Miller J. W., Urbinati C. R., Teng-Umnuay P., Stenberg M. G., Byrne B. J., Thornton C. A. and Swanson M. S. (2000 ). Recruitment of human muscleblind proteins to (CUG)n expansions associated with myotonic dystrophy. EMBO J. 19, 4439-4448.

    Not in our library10.1093/emboj/19.17.4439

  111. 111.

    Miñones-Moyano E., Porta S., Escaramís G., Rabionet R., Iraola S., Kagerbauer B., Espinosa-Parrilla Y., Ferrer I., Estivill X. and Martí E. (2011 ). MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum. Mol. Genet. 20, 3067-3078.

    Not in our library10.1093/hmg/ddr210

  112. 112.

    Molliex A., Temirov J., Lee J., Coughlin M., Kanagaraj A. P., Kim H. J., Mittag T. and Taylor J. P. (2015 ). Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. Cell 163, 123-133.

    Not in our library10.1016/j.cell.2015.09.015

  113. 113.

    Moseley M. L., Zu T., Ikeda Y., Gao W., Mosemiller A. K., Daughters R. S., Chen G., Weatherspoon M. R., Clark H. B., Ebner T. J. et al. (2006 ). Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. Nat. Genet. 38, 758-769.

    Not in our library10.1038/ng1827

  114. 114.

    Motley W. W., Talbot K. and Fischbeck K. H. (2010 ). GARS axonopathy: not every neuron's cup of tRNA. Trends Neurosci. 33, 59-66.

    Not in our library10.1016/j.tins.2009.11.001

  115. 115.
    ALS/FTD Mutation-Induced Phase Transition of FUS Liquid Droplets and Reversible Hydrogels into Irreversible Hydrogels Impairs RNP Granule Function · 2015
    No notice
  116. 116.

    Nangle L. A., Zhang W., Xie W., Yang X.-L. and Schimmel P. (2007 ). Charcot-Marie-Tooth disease-associated mutant tRNA synthetases linked to altered dimer interface and neurite distribution defect. Proc. Natl. Acad. Sci. USA 104, 11239-11244.

    Not in our library10.1073/pnas.0705055104

  117. 117.

    Nelson P. T. and Wang W.-X. X. (2010 ). MiR-107 is reduced in Alzheimer's disease brain neocortex: validation study. J. Alzheimers Dis. 21, 75-79.

    Not in our library10.3233/jad-2010-091603

  118. 118.

    Neumann M., Sampathu D. M., Kwong L. K., Truax A. C., Micsenyi M. C., Chou T. T., Bruce J., Schuck T., Grossman M., Clark C. M. et al. (2006 ). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130-133.

    Not in our library10.1126/science.1134108

  119. 119.
    Impaired protein translation in Drosophila models for Charcot–Marie–Tooth neuropathy caused by mutant tRNA synthetases · 2015
    Corrected
  120. 120.

    Oh S. Y., He F., Krans A., Frazer M., Taylor J. P., Paulson H. L. and Todd P. K. (2015 ). RAN translation at CGG repeats induces ubiquitin proteasome system impairment in models of fragile X-associated tremor ataxia syndrome. Hum. Mol. Genet. 24, 4317-4326.

    Not in our library10.1093/hmg/ddv165

  121. 121.

    Packer A. N., Xing Y., Harper S. Q., Jones L. and Davidson B. L. (2008 ). The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease. J. Neurosci. 28, 14341-14346.

    Not in our library10.1523/jneurosci.2390-08.2008

  122. 122.

    Paushkin S. V., Patel M., Furia B. S., Peltz S. W. and Trotta C. R. (2004 ). Identification of a human endonuclease complex reveals a link between tRNA splicing and pre-mRNA 3′ end formation. Cell 117, 311-321.

    Not in our library10.1016/s0092-8674(04)00342-3

  123. 123.

    Pieretti M., Zhang F. P., Fu Y.-H., Warren S. T., Oostra B. A., Caskey C. T. and Nelson D. L. (1991 ). Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 66, 817-822.

    Not in our library10.1016/0092-8674(91)90125-i

  124. 124.

    Polymenidou M., Lagier-Tourenne C., Hutt K. R., Huelga S. C., Moran J., Liang T. Y., Ling S.-C. C., Sun E., Wancewicz E., Mazur C. et al. (2011 ). Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat. Neurosci. 14, 459-468.

    Not in our library10.1038/nn.2779

  125. 125.

    Prensner J. R. and Chinnaiyan A. M. (2011 ). The emergence of lncRNAs in cancer biology. Cancer Discov. 1, 391-407.

    Not in our library10.1158/2159-8290.cd-11-0209

  126. 126.

    Renton A. E., Majounie E., Waite A., Simón-Sánchez J., Rollinson S., Gibbs J. R., Schymick J. C., Laaksovirta H., van Swieten J. C., Myllykangas L. et al. (2011 ). A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257-268.

    Not in our library10.1016/j.neuron.2011.09.010

  127. 127.

    Russ J., Liu E. Y., Wu K., Neal D., Suh E., Irwin D. J., McMillan C. T., Harms M. B., Cairns N. J., Wood E. M. et al. (2015 ). Hypermethylation of repeat expanded C9orf72 is a clinical and molecular disease modifier. Acta Neuropathol. 129, 39-52.

    Not in our library10.1007/s00401-014-1365-0

  128. 128.

    Russell A. P., Wada S., Vergani L., Hock M. B., Lamon S., Léger B., Ushida T., Cartoni R., Wadley G. D., Hespel P. et al. (2013 ). Disruption of skeletal muscle mitochondrial network genes and miRNAs in amyotrophic lateral sclerosis. Neurobiol. Dis. 49, 107-117.

    Not in our library10.1016/j.nbd.2012.08.015

  129. 129.

    Sareen D., O'Rourke J. G., Meera P., Muhammad A. K. M. G., Grant S., Simpkinson M., Bell S., Carmona S., Ornelas L., Sahabian A. et al. (2013 ). Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci. Transl. Med. 5, 208ra149

    Not in our library10.1126/scitranslmed.3007529

  130. 130.

    Scekic-Zahirovic J., Sendscheid O., El Oussini H., Jambeau M., Sun Y., Mersmann S., Wagner M., Dieterlé S., Sinniger J., Dirrig-Grosch S. et al. (2016 ). Toxic gain of function from mutant FUS protein is crucial to trigger cell autonomous motor neuron loss. EMBO J. 35, 1077-1097.

    Not in our library10.15252/embj.201592559

  131. 131.

    Schaffer A. E., Eggens V. R. C., Caglayan A. O., Reuter M. S., Scott E., Coufal N. G., Silhavy J. L., Xue Y., Kayserili H., Yasuno K. et al. (2014 ). CLP1 founder mutation links tRNA splicing and maturation to cerebellar development and neurodegeneration. Cell 157, 651-663.

    Not in our library10.1016/j.cell.2014.03.049

  132. 132.

    Schonrock N., Humphreys D. T., Preiss T. and Götz J. (2012 ). Target gene repression mediated by miRNAs miR-181c and miR-9 both of which are down-regulated by amyloid-β. J. Mol. Neurosci. 46, 324-335.

    Not in our library10.1007/s12031-011-9587-2

  133. 133.

    Schwarz D., Hutvágner G., Du T., Xu Z., Aronin N. and Zamore P. D. (2003 ). Asymmetry in the assembly of the RNAi enzyme complex. Cell 115, 199-208.

    Not in our library10.1016/s0092-8674(03)00759-1

  134. 134.

    Sellier C., Rau F., Liu Y., Tassone F., Hukema R. K., Gattoni R., Schneider A., Richard S., Willemsen R., Elliott D. J. et al. (2010 ). Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients. EMBO J. 29, 1248-1261.

    Not in our library10.1038/emboj.2010.21

  135. 135.

    Sellier C., Freyermuth F., Tabet R., Tran T., He F., Ruffenach F., Alunni V., Moine H., Thibault C., Page A. et al. (2013 ). Sequestration of DROSHA and DGCR8 by expanded CGG RNA repeats alters microRNA processing in fragile X-associated tremor/ataxia syndrome. Cell Rep. 3, 869-880.

    Not in our library10.1016/j.celrep.2013.02.004

  136. 136.

    Sephton C. F., Cenik C., Kucukural A., Dammer E. B., Cenik B., Han Y., Dewey C. M., Roth F. P., Herz J., Peng J. et al. (2011 ). Identification of neuronal RNA targets of TDP-43-containing ribonucleoprotein complexes. J. Biol. Chem. 286, 1204-1215.

    Not in our library10.1074/jbc.m110.190884

  137. 137.
    ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function · 2016
    No notice
  138. 138.

    Shiga A., Ishihara T., Miyashita A., Kuwabara M., Kato T., Watanabe N., Yamahira A., Kondo C., Yokoseki A., Takahashi M. et al. (2012 ). Alteration of POLDIP3 splicing associated with loss of function of TDP-43 in tissues affected with ALS. PLoS ONE 7, e43120

    Not in our library10.1371/journal.pone.0043120

  139. 139.

    Shioya M., Obayashi S., Tabunoki H., Arima K., Saito Y., Ishida T. and Satoh J. (2010 ). Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3. Neuropathol. Appl. Neurobiol. 36, 320-330.

    Not in our library10.1111/j.1365-2990.2010.01076.x

  140. 140.
    Spatial patterning of P granules by RNA-induced phase separation of the intrinsically-disordered protein MEG-3 · 2016
    No notice
  141. 141.

    Sofola O. A., Jin P., Qin Y., Duan R., Liu H., de.Haro M., Nelson D. L. and Botas J. (2007 ). RNA-binding proteins hnRNP A2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a Drosophila model of FXTAS. Neuron 55, 565-571.

    Not in our library10.1016/j.neuron.2007.07.021

  142. 142.

    Sreedharan J., Blair I. P., Tripathi V. B., Hu X., Vance C., Rogelj B., Ackerley S., Durnall J. C., Williams K. L., Buratti E. et al. (2008 ). TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319, 1668-1672.

    Not in our library10.1126/science.1154584

  143. 143.

    Strong M. J., Volkening K., Hammond R., Yang W., Strong W., Leystra-Lantz C. and Shoesmith C. (2007 ). TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein. Mol. Cell. Neurosci. 35, 320-327.

    Not in our library10.1016/j.mcn.2007.03.007

  144. 144.

    Su Z., Zhang Y., Gendron T. F., Bauer P. O., Chew J., Yang W.-Y., Fostvedt E., Jansen-West K., Belzil V. V., Desaro P. et al. (2014 ). Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS. Neuron 83, 1043-1050.

    Not in our library10.1016/j.neuron.2014.07.041

  145. 145.

    Sullenger B. A. and Nair S. (2016 ). From the RNA world to the clinic. Science 352, 1417-1420.

    Not in our library10.1126/science.aad8709

  146. 146.
    Molecular Determinants and Genetic Modifiers of Aggregation and Toxicity for the ALS Disease Protein FUS/TLS · 2011
    No notice
  147. 147.

    Sunwoo J.-S., Lee S.-T., Im W., Lee M., Byun J.-I., Jung K.-H., Park K.-I., Jung K.-Y., Lee S., Chu K. et al. (2016 ). Altered expression of the long noncoding RNA NEAT1 in huntington's disease. Mol. Neurobiol. 54, 1577-1586.

    Not in our library10.1007/s12035-016-9928-9

  148. 148.

    Tan J. Y., Vance K. W., Varela M. A., Sirey T., Watson L. M., Curtis H. J., Marinello M., Alves S., Steinkraus B. R., Cooper S. et al. (2014 ). Cross-talking noncoding RNAs contribute to cell-specific neurodegeneration in SCA7. Nat. Struct. Mol. Biol. 21, 955-961.

    Not in our library10.1038/nsmb.2902

  149. 149.

    Taneja K. L., McCurrach M., Schalling M., Housman D. and Singer R. H. (1995 ). Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. J. Cell Biol. 128, 995-1002.

    Not in our library10.1083/jcb.128.6.995

  150. 150.

    Thum T. (2012 ). MicroRNA therapeutics in cardiovascular medicine. EMBO Mol. Med. 4, 3-14.

    Not in our library10.1002/emmm.201100191

  151. 151.
    MicroRNA-206: A Potential Circulating Biomarker Candidate for Amyotrophic Lateral Sclerosis · 2014
    No notice
  152. 152.

    Tollervey J. R., Curk T., Rogelj B., Briese M., Cereda M., Kayikci M., König J., Hortobágyi T., Nishimura A. L., Zupunski V. et al. (2011 ). Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat. Neurosci. 14, 452-458.

    Not in our library10.1038/nn.2778

  153. 153.

    Tripathi V., Ellis J. D., Shen Z., Song D. Y., Pan Q., Watt A. T., Freier S. M., Bennett P. A., Sharma A., Bubulya P. A. et al. (2010 ). The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol. Cell 39, 925-938.

    Not in our library10.1016/j.molcel.2010.08.011

  154. 154.

    Trotta C., Paushkin S. V., Patel M., Li H. and Peltz S. W. (2006 ). Cleavage of pre-tRNAs by the splicing endonuclease requires a composite active site. Nature 441, 375-377.

    Not in our library10.1038/nature04741

  155. 155.

    Tsai K.-J., Yang C.-H., Fang Y.-H., Cho K.-H., Chien W.-L., Wang W.-T., Wu T.-W., Lin C.-P., Fu W.-M. and Shen C.-K. (2010 ). Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U. J. Exp. Med. 207, 1661-1673.

    Not in our library10.1084/jem.20092164

  156. 156.

    Van Deerlin V. M., Leverenz J. B., Bekris L. M., Bird T. D., Yuan W., Elman L. B., Clay D., Wood E. M., Chen-Plotkin A. S., Martinez-Lage M. et al. (2008 ). TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet. Neurol. 7, 409-416.

    Not in our library10.1016/s1474-4422(08)70071-1

  157. 157.

    Vance C., Rogelj B., Hortobágyi T., De Vos K. J., Nishimura A. L., Sreedharan J., Hu X., Smith B., Ruddy D., Wright P. et al. (2009 ). Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208-1211.

    Not in our library10.1126/science.1165942

  158. 158.

    Vassar R., Bennett B. D., Babu-Khan S., Kahn S., Mendiaz E. D., Denis P., Teplow D. B., Ross S., Amarante P., Loeloff R. et al. (1999 ). Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735-741.

    Not in our library10.1126/science.286.5440.735

  159. 159.
    TDP-43-Mediated Neuron Loss In Vivo Requires RNA-Binding Activity · 2010
    No notice
  160. 160.

    Wang W.-X., Rajeev B. W., Stromberg A. J., Ren N., Tang G., Huang Q., Rigoutsos I. and Nelson P. T. (2008 ). The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J. Neurosci. 28, 1213-1223.

    Not in our library10.1523/jneurosci.5065-07.2008

  161. 161.

    Wang W.-X., Huang Q., Hu Y., Stromberg A. J. and Nelson P. T. (2011 ). Patterns of microRNA expression in normal and early Alzheimer's disease human temporal cortex: white matter versus gray matter. Acta Neuropathol. 121, 193-205.

    Not in our library10.1007/s00401-010-0756-0

  162. 162.

    Wang E. T., Cody N. A. L., Jog S., Biancolella M., Wang T. T., Treacy D. J., Luo S., Schroth G. P., Housman D. E., Reddy S. et al. (2012a ). Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins. Cell 150, 710-724.

    Not in our library10.1016/j.cell.2012.06.041

  163. 163.

    Wang I.-F., Guo B.-S., Liu Y.-C., Wu C.-C., Yang C.-H., Tsai K.-J. and Shen C.-K. J. (2012b ). Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. Proc. Natl. Acad. Sci. USA 109, 15024-15029.

    Not in our library10.1073/pnas.1206362109

  164. 164.

    Watts G. D., Wymer J., Kovach M. J., Mehta S. G., Mumm S., Darvish D., Pestronk A., Whyte M. P. and Kimonis V. E. (2004 ). Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat. Genet. 36, 377-381.

    Not in our library10.1038/ng1332

  165. 165.

    Wheeler T. M., Leger A. J., Pandey S. K., MacLeod A. R., Nakamori M., Cheng S. H., Wentworth B. M., Bennett C. F. and Thornton C. A. (2012 ). Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488, 111-115.

    Not in our library10.1038/nature11362

  166. 166.

    Wils H., Kleinberger G., Janssens J., Pereson S., Joris G., Cuijt I., Smits V., Ceuterick-de Groote C., Broeckhoven C. and Kumar-Singh S. (2010 ). TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. USA 107, 3858-3863.

    Not in our library10.1073/pnas.0912417107

  167. 167.

    Wu W., Sun M., Zou G.-M. and Chen J. (2007a ). MicroRNA and cancer: current status and prospective. Int. J. Cancer 120, 953-960.

    Not in our library10.1002/ijc.22454

  168. 168.

    Wu D., Yu W., Kishikawa H., Folkerth R. D., Iafrate J., Shen Y., Xin W., Sims K. and Hu G. (2007b ). Angiogenin loss-of-function mutations in amyotrophic lateral sclerosis. Ann. Neurol. 62, 609-617.

    Not in our library10.1002/ana.21221

  169. 169.

    Xiang S., Kato M., Wu L. C., Lin Y., Ding M., Zhang Y., Yu Y. and McKnight S. L. (2015 ). The LC domain of hnRNPA2 adopts similar conformations in hydrogel polymers, liquid-like droplets, and nuclei. Cell 163, 829-839.

    Not in our library10.1016/j.cell.2015.10.040

  170. 170.

    Xie W., Nangle L. A., Zhang W., Schimmel P. and Yang X.-L. (2007 ). Long-range structural effects of a Charcot-Marie-Tooth disease-causing mutation in human glycyl-tRNA synthetase. Proc. Natl. Acad. Sci. USA 104, 9976-9981.

    Not in our library10.1073/pnas.0703908104

  171. 171.

    Xu Y.-F., Gendron T., Zhang Y.-J., Lin W.-L., D'Alton S., Sheng H., Casey M. C., Tong J., Knight J., Yu X. et al. (2010 ). Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J. Neurosci. 30, 10851-10859.

    Not in our library10.1523/jneurosci.1630-10.2010

  172. 172.

    Yang M., Liang C., Swaminathan K., Herrlinger S., Lai F., Shiekhattar R., and Chen J.-F. (2016 ). A C9ORF72/SMCR8-containing complex regulates ULK1 and plays a dual role in autophagy. Science Advances 2, e1601167

    Not in our library10.1126/sciadv.1601167

  173. 173.

    Yamasaki S., Ivanov P., Hu G. F. and Anderson P. (2009 ). Angiogenin cleaves tRNA and promotes stress-induced translational repression. J. Cell. Biol. 185, 35-42.

    Not in our library10.1083/jcb.200811106

  174. 174.
    Transgenic Rat Model of Neurodegeneration Caused by Mutation in the TDP Gene · 2010
    No notice
  175. 175.

    Zovoilis A., Agbemenyah H. Y., Agis-Balboa R. C., Stilling R. M., Edbauer D., Rao P., Farinelli L., Delalle I., Schmitt A., Falkai P. et al. (2011 ). microRNA-34c is a novel target to treat dementias. EMBO J. 30, 4299-4308.

    Not in our library10.1038/emboj.2011.327

  176. 176.

    Zu T., Gibbens B., Doty N. S., Gomes-Pereira M., Huguet A., Stone M. D., Margolis J., Peterson M., Markowski T. W., Ingram M. A. et al. (2011 ). Non-ATG-initiated translation directed by microsatellite expansions. Proc. Natl. Acad. Sci. USA 108, 260-265.

    Not in our library10.1073/pnas.1013343108

  177. 177.

    Zu T., Liu Y., Bañez-Coronel M., Reid T., Pletnikova O., Lewis J., Miller T. M., Harms M. B., Falchook A. E., Subramony S. H. et al. (2013 ). RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc. Natl. Acad. Sci. USA 110, E4968-E4977.

    Not in our library10.1073/pnas.1315438110

Cited by papers we hold 7

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.